Performance of the Glucose Management Indicator (GMI) in Type 2 Diabetes
Clinical Chemistry · 03.04.2023 · 69 (4) · 422-428
DOI: 10.1093/clinchem/hvac210 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical Chemistry, online erschienen am 04.02.2023. Verfasst von Michael Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIA NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
The glucose management indicator (GMI) is an estimated measure of hemoglobin A1c (HbA1c) recommended for the management of persons with diabetes using continuous glucose monitoring (CGM). However, GMI was derived primarily in young adults with type 1 diabetes, and its performance in patients with type 2 diabetes is poorly characterized.
Methods
We conducted a prospective cohort study in 144 adults with obstructive sleep apnea and type 2 diabetes not using insulin (mean age: 59.4 years; 45.1% female). HbA1c was measured at the study screening visit. Participants simultaneously wore 2 CGM sensors (Dexcom G4 and Abbott Libre Pro) for up to 4 weeks (2 weeks at baseline and 2 weeks at the 3-month follow-up visit). GMI was calculated using all available CGM data for each sensor.
Results
Median wear time was 27 days (IQR: 23–29) for the Dexcom G4 and 28 days (IQR: 24–29) for the Libre Pro. The mean difference between HbA1c and GMI was small (0.12–0.14 percentage points) (approximately 2 mmol/mol). However, the 2 measures were only moderately correlated (r = 0.68–0.71), and there was substantial variability in GMI at any given value of HbA1c (root mean squared error: 0.66–0.69 percentage points [7 to 8 mmol/mol]). Between 36% and 43% of participants had an absolute difference between HbA1c and GMI ≥0.5 percentage points (≥5 mmol/mol), and 9% to 18% had an absolute difference >1 percentage points (>11 mmol/mol). Discordance was higher in the Libre Pro than the Dexcom G4.
Conclusions
GMI may be an unreliable measure of glycemic control for patients with type 2 diabetes and should be interpreted cautiously in clinical practice. Clinicaltrials.gov Registration Number: NCT02454153.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
- Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
- Division of Pulmonary, Critical Care, and Sleep Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA.
ORCID-Profile: Michael Fang, Mary R Rooney, Justin B Echouffo-Tcheugui, Elizabeth Selvin
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- NIA NIH HHS
- NIH/NHLBI
- NIH/NIDDK
- NIH/NIA
Zitieren
APA
Fang, M., Wang, D., Rooney, M. R., Echouffo-Tcheugui, J. B., Coresh, J., Aurora, R. N., Punjabi, N. M., & Selvin, E. (2023). Performance of the Glucose Management Indicator (GMI) in Type 2 Diabetes. Clinical Chemistry, 69(4), 422-428. https://doi.org/10.1093/clinchem/hvac210
Vancouver
Fang M, Wang D, Rooney MR, Echouffo-Tcheugui JB, Coresh J, Aurora RN, et al. Performance of the Glucose Management Indicator (GMI) in Type 2 Diabetes. Clinical Chemistry. 2023;69(4):422-428. doi:10.1093/clinchem/hvac210
BibTeX
@article{Fang2023,
author = {Fang, Michael and Wang, Dan and Rooney, Mary R and Echouffo-Tcheugui, Justin B and Coresh, Josef and Aurora, R Nisha and Punjabi, Naresh M and Selvin, Elizabeth},
title = {Performance of the Glucose Management Indicator (GMI) in Type 2 Diabetes},
journal = {Clinical Chemistry},
year = {2023},
volume = {69},
number = {4},
pages = {422--428},
doi = {10.1093/clinchem/hvac210}
}
EUVIMED